100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec

Bayer On the Rebound - Is One Still Ahead for Evotec?

Bayer has had some turbulent years. That is no secret. Anyone who invested in the Leverkusen-based company needed strong nerves and patience. But the tide appears to have turned. DZ Bank also recently sent a signal, raising its recommendation for Bayer stock to "Hold." The new price target is now EUR 44. Previously, analysts were significantly more skeptical. What has changed? Above all, the predictability of the glyphosate risks. For a long time, the issue was a black hole for investors. Now everyone is looking toward the end of April 2026. That is when important hearings are scheduled before the US Supreme Court. Should the justices definitively limit the liability risks, the sword of Damocles would be defused.

Meanwhile, Bayer is delivering impressive operational figures. The drug Kerendia, in particular, is shining. It is used to treat heart failure. In this market alone, there are around 7.5 million patients in the EU. Revenue skyrocketed by nearly 93% in the fourth quarter of 2025. That amounts to EUR 264 million in just three months. Management is already dreaming of peak sales of EUR 3 billion per year. The target for operating profit (EBITDA) also remains firmly in sight at around EUR 10 billion for the current year. The stock has already reacted, gaining over 100% in the last twelve months. It is currently trading steadily above EUR 40.

At the same time, Evotec is also in significantly better shape. Sentiment in the drug discovery sector is brightening slightly. Evotec is benefiting from this more positive trend. The company is regarded as an important partner for the major pharmaceutical groups. When, for example, giants like Bayer step up their operational activities again, service providers like Evotec often follow suit. The stock recently showed signs of bottoming out. Investors value the Hamburg-based company's broad pipeline, and we can now move into a phase of cautious optimism as the market calms down around Evotec. The era of panic selling may be over. The Tubulis deal is also expected to close in the second quarter and should boost the balance sheet for now. While the turnaround has arrived, or may be coming soon for Bayer and Evotec, something bigger is brewing at the small company Vidac Pharma.

Vidac Pharma: Medical Breakthroughs and Bold Investors

If attention shifts away from larger pharmaceutical players such as Bayer and Evotec, it increasingly turns toward smaller, highly specialized companies like Vidac Pharma. The London-based company operates in a completely different "weight class", focusing on a metabolic approach to oncology rather than directly targeting cancer cell destruction. It is all about the enzyme hexokinase-2. In cancer cells, this enzyme is often misdirected. It prevents natural cell death. Vidac's drugs are designed to reverse this process.

One notable data point disclosed in March 2026 came from a compassionate-use or therapeutic case involving a pediatric patient with a severe brain tumor who was treated with the investigational candidate VDA-1102 ahead of surgery. The objective was to assess whether metabolic stabilization of the tumor environment could be achieved prior to intervention. According to the company's report, improvements in metabolic markers were observed, and subsequent medical procedures were completed successfully. Today, the girl is six years old. She leads a normal life without cognitive impairments. This is more than just a dry statistic. It is "proof" of the effectiveness of the research. Scientists like Professor Cyril Cohen confirm the significance of this approach. It is about normalizing the tumor microenvironment. That is the key to success.

But research costs money. And this is where the news from March 11, 2026, comes into play. It sends a strong signal to the capital market. The major shareholders and directors of Vidac Pharma are taking an unusual path. They have announced plans to sell their own share packages. But not to pocket profits. They intend to use the net proceeds to provide financial support to the company. The money will go directly toward covering operating costs for 2026. This is an act of deep trust. Anyone who liquidates their own shares to secure the operation of their own company believes in the breakthrough. Management is thus demonstrating that it is willing to take personal risks. It is a commitment to the company's location and its own pipeline.

The Chance to Double: Why the EUR 1 Mark Is Now Within Reach

Vidac Pharma shares are currently trading at around EUR 0.56. The company has weathered a difficult period on the stock market. The share price has fallen sharply on several occasions in the past. But this is precisely where the opportunity lies. We often observe that stocks initiate a strong rebound following a downtrend. Several positive factors are now converging at Vidac Pharma. The clinical pipeline is robust. An important Phase 2b study for precancerous skin lesions is underway in Germany, and the results could be promising.

In addition, the company plans to expand into the US, coupled with a listing on the OTC markets. This would facilitate access to American investors. A roadshow through Germany and Austria in April should also generate new attention. When putting these pieces of the puzzle together, a clear picture emerges. Fundamentally, the company is already significantly further along than the current price might suggest. The EUR 1.00 mark is therefore a very real target for the share price and would mark a return to former strength. For investors entering at the current level, this represents an opportunity to double their investment. Of course, the risks here are also high, a fact that should not be forgotten amid all the euphoria, but as a component of an overall portfolio, it is worth considering.

Vidac Pharma remains, by virtue of its current size alone, a highly speculative investment. This is biotechnology. However, the combination of genuine medical potential and financial backing from its own directors is relatively rare. The stock could regain momentum after its recent price decline, and sentiment could shift back into positive territory. It is a classic turnaround story in the making. Those willing to swim against the tide could be rewarded here. The scientific foundation appears solid. The management team is experienced. And the market for cancer therapies is growing steadily. Vidac Pharma has positioned itself in a niche that offers significant potential.

Conclusion: Three Stocks, Three Paths

Bayer likely has the worst behind it. Its operational strength in drugs like Kerendia is increasingly offsetting the legal risks. Evotec remains a solid player that could benefit from the general market recovery. Vidac Pharma, on the other hand, is a kind of gamble or a wild card in the portfolio. Its successes in treating brain tumors and the commitment of insiders are arguments in favor of buying. Following the price drop, the current level of EUR 0.56 offers an entry opportunity, and the prospect of a doubling toward EUR 1.00 is realistic. So far, the company has delivered facts rather than just promises. Viewed objectively, it is a highly speculative yet passionate opportunity for significant price gains.